BIO-TECHNE Corp (TECH)
Health Care · Life Sciences Tools & Services · US stock · S&P 500 component
$72.57
▲ +0.05 (0.07%)
Fair valueOvervalued
$33 −54.9% to fair value
$16fair band $23–$43$49
Day's range
$72.45 – $72.59
52-week range
$43.02 – $72.69
About BIO-TECHNE Corp
Bio-Techne develops and manufactures reagents, instruments and diagnostic products used in life science research and clinical testing. Its proteins, antibodies and assay kits are used by academic, biotech and pharmaceutical researchers, while its protein analysis instruments and its diagnostics and genomics products serve laboratories and clinical customers. The business is organised into a protein sciences group and a diagnostics and spatial biology group.
Revenue comes from repeat orders of consumable reagents and kits, alongside instruments and diagnostic products. It totals $1.2 billion over the last twelve months, growing at 2.2% a year across three years. The operating margin is 20.7%, and the business earns a profit of 9% on the capital invested in it. Bio-Techne carries net debt of 0.1 times EBITDA, and the dividend yield is 0.6%. On the site's X-Ray Score it receives 40 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $43.02 – $72.69Volume 2,646,300Daily, split-adjusted
Vitals
Market cap$11.4B
52-week range$43.02 – $72.69
Volume (last day)2,646,300
P/E (TTM)62.6
EBIT / EV yield2.2%
Free-cash-flow yield2.3%
Dividend yield0.6%
Revenue (TTM)$1.2B
Net income (TTM)$182M
Operating margin20.7%
Return on capital8.9%
Debt incl. leases$289M
Cash & securities$265M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$33model spread $32 – $34
Overvalued
−54.9% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $73
Undervalued < $23Fair $23 – $43Overvalued > $43
10-year DCF (market-scaled)
$29
Peer multiples
$37
Earnings power floor (not blended)
$13
Fundamentals-adjusted multiple
$33
Growth the price implies
31.1%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
11/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield2.2%
Free-cash-flow yield2.3%
Fair value vs price0.5×
Growth
Weak
26/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)2.2%
EPS growth (3y)-13.0%
Growth consistency70%
Profitability
Weak
46/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital8.9%
Operating margin20.7%
Gross profitability30.9%
Financial health
Strong
83/100
Balance sheet looks strong: debt is well covered.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA0.1×
Interest cover26.2×
Dividends
Weak
40/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield0.6%
Dividends vs free cash flow24%
Dividend growth-0.2%
Quarterly results: last 6 quarters
+4.2%
Mar '25
+3.5%
Jun '25
-1.0%
Sep '25
-0.4%
Dec '25
-1.5%
Mar '26
+1.3%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $321M.
Compare with peers
MTD Mettler Toledo Interna...50 A Agilent Technologies,...42 IQV Iqvia Holdings Inc.42 ILMN Illumina, Inc.39Other Life Sciences Tools & Services companies by X-Ray Score.
Fundamentals checklist
● 6 Good · ● 4 Average · ● 6 BadCash quality
Earnings backed by cashAverage
Free-cash-flow yieldBad
Risk models
Altman Z''Good
Piotroski F-ScoreGood
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Average
Revenue growth (3y)Bad
Growth consistencyBad
Balance sheet
Current ratioGood
Net debt / EBITDAGood
Interest coverGood
Valuation
Fair value vs priceBad
EBIT / EV yieldBad
Profitability
Return on invested capitalAverage
Operating marginGood
Gross profitabilityAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 44/100.
Financials
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B |
| Operating income | $297M | $299M | $207M | $102M | $252M |
| Net income | $272M | $285M | $168M | $73M | $182M |
| Operating cash flow | $325M | $254M | $299M | $288M | $292M |
| Operating margin | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Free cash flow | $280M | $216M | $236M | $257M | $263M |
| Diluted EPS | $1.66 | $1.76 | $1.05 | $0.46 | $1.16 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 2 neutral · 2 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 72.51 | Bullish |
| EMA 10 | 72.51 | Bullish |
| SMA 20 | 72.50 | Bullish |
| EMA 20 | 72.46 | Bullish |
| SMA 50 | 72.35 | Bullish |
| EMA 50 | 71.54 | Bullish |
| SMA 100 | 68.26 | Bullish |
| EMA 100 | 68.56 | Bullish |
| SMA 200 | 62.57 | Bullish |
| EMA 200 | 64.84 | Bullish |
Oscillators (daily)
| RSI (14) | 58.60 | Neutral |
| MACD (12, 26) | 0.10 | Bullish |
| Momentum (12) | 0.14 | Bullish |
| Stochastic %K (14) | 85.71 | Bearish |
| Williams %R (14) | -14.29 | Bearish |
| CCI (20) | 48.85 | Neutral |
Pivot points (classic, last session)
S3 72.34 | S2 72.40 | S1 72.48 | Pivot 72.54 | R1 72.62 | R2 72.68 | R3 72.76 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
0.40 USD
Yield on today's price
0.55%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 24 Aug 2026 | 0.0800 |
| 17 Aug 2026 | 0.0800 |
| 18 May 2026 | 0.0800 |
| 13 Feb 2026 | 0.0800 |
| 17 Nov 2025 | 0.0800 |
| 18 Aug 2025 | 0.0800 |
| 19 May 2025 | 0.0800 |
| 14 Feb 2025 | 0.0800 |
| 8 Nov 2024 | 0.0800 |
| 19 Aug 2024 | 0.0800 |
| 10 May 2024 | 0.0800 |
| 9 Feb 2024 | 0.0800 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
TECH SEC filings
23 Sep 2026
8-KSEC EDGAR
Shareholder vote results; Regulation FD disclosure
14 Sep 2026
8-KSEC EDGAR
Other events
24 Aug 2026
10-KSEC EDGAR
Annual report
12 Aug 2026
8-KSEC EDGAR
Results of operations; Other events
26 Jun 2026
8-KSEC EDGAR
Entered a material agreement; Director or officer change
25 Jun 2026
8-KSEC EDGAR
Regulation FD disclosure
6 May 2026
10-QSEC EDGAR
Quarterly report
6 May 2026
8-KSEC EDGAR
Results of operations; Other events
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.